JP2009543811A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009543811A5 JP2009543811A5 JP2009519765A JP2009519765A JP2009543811A5 JP 2009543811 A5 JP2009543811 A5 JP 2009543811A5 JP 2009519765 A JP2009519765 A JP 2009519765A JP 2009519765 A JP2009519765 A JP 2009519765A JP 2009543811 A5 JP2009543811 A5 JP 2009543811A5
- Authority
- JP
- Japan
- Prior art keywords
- vol
- patent document
- pat
- drug
- gastroenterology
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 description 9
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- 102000016924 KATP Channels Human genes 0.000 description 2
- 108010053914 KATP Channels Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 229940124599 anti-inflammatory drug Drugs 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000003118 drug derivative Substances 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- RWSOTUBLDIXVET-UHFFFAOYSA-M hydrosulfide Chemical compound [SH-] RWSOTUBLDIXVET-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- JYNPQXKLKQHEFP-UHFFFAOYSA-N CCCCC1(C(C(=C(C(=C1C)C)C)NC)C(=O)O)C2=CC=CC=C2 Chemical compound CCCCC1(C(C(=C(C(=C1C)C)C)NC)C(=O)O)C2=CC=CC=C2 JYNPQXKLKQHEFP-UHFFFAOYSA-N 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 108090000026 Caveolin 1 Proteins 0.000 description 1
- 102100035888 Caveolin-1 Human genes 0.000 description 1
- 102000001327 Chemokine CCL5 Human genes 0.000 description 1
- 108010055166 Chemokine CCL5 Proteins 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000000795 Galectin 1 Human genes 0.000 description 1
- 108010001498 Galectin 1 Proteins 0.000 description 1
- 206010059024 Gastrointestinal toxicity Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010035766 P-Selectin Proteins 0.000 description 1
- 102100023472 P-selectin Human genes 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 108050003267 Prostaglandin G/H synthase 2 Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003430 antimalarial agent Substances 0.000 description 1
- 229940033495 antimalarials Drugs 0.000 description 1
- 208000037849 arterial hypertension Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000007248 cellular mechanism Effects 0.000 description 1
- VDTNKXSVUGXUOJ-UHFFFAOYSA-N chembl2441358 Chemical compound NC(=S)C1=CC=C(O)C=C1 VDTNKXSVUGXUOJ-UHFFFAOYSA-N 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 229940127243 cholinergic drug Drugs 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000112 colonic effect Effects 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- DCOPUUMXTXDBNB-UHFFFAOYSA-N diclofenac Chemical compound OC(=O)CC1=CC=CC=C1NC1=C(Cl)C=CC=C1Cl DCOPUUMXTXDBNB-UHFFFAOYSA-N 0.000 description 1
- 229960001259 diclofenac Drugs 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 231100000414 gastrointestinal toxicity Toxicity 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 1
- 229960004963 mesalazine Drugs 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 231100000417 nephrotoxicity Toxicity 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000000050 smooth muscle relaxant Substances 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000019086 sulfide ion homeostasis Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US80763906P | 2006-07-18 | 2006-07-18 | |
| US60/807,639 | 2006-07-18 | ||
| US88718807P | 2007-01-30 | 2007-01-30 | |
| US60/887,188 | 2007-01-30 | ||
| PCT/CA2007/001273 WO2008009118A1 (en) | 2006-07-18 | 2007-07-18 | 4-hydroxythiobenzamide derivatives of drugs |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009543811A JP2009543811A (ja) | 2009-12-10 |
| JP2009543811A5 true JP2009543811A5 (https=) | 2010-12-16 |
| JP5529534B2 JP5529534B2 (ja) | 2014-06-25 |
Family
ID=38956479
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519765A Expired - Fee Related JP5529534B2 (ja) | 2006-07-18 | 2007-07-18 | ４−ヒドロキシチオベンズアミド薬剤誘導体 |
| JP2009519769A Active JP5408719B2 (ja) | 2006-07-18 | 2007-07-18 | 非ステロイド系抗炎症薬の硫化水素誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009519769A Active JP5408719B2 (ja) | 2006-07-18 | 2007-07-18 | 非ステロイド系抗炎症薬の硫化水素誘導体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US8314140B2 (https=) |
| EP (2) | EP2041108B1 (https=) |
| JP (2) | JP5529534B2 (https=) |
| KR (2) | KR101450653B1 (https=) |
| AU (2) | AU2007276679B2 (https=) |
| BR (2) | BRPI0714330A2 (https=) |
| CA (2) | CA2658429A1 (https=) |
| DK (1) | DK2057139T3 (https=) |
| ES (1) | ES2437223T3 (https=) |
| IL (2) | IL196229A (https=) |
| MX (2) | MX2009000749A (https=) |
| NO (2) | NO20090764L (https=) |
| NZ (1) | NZ573996A (https=) |
| PL (1) | PL2057139T3 (https=) |
| PT (1) | PT2057139E (https=) |
| RU (2) | RU2468019C2 (https=) |
| WO (2) | WO2008009118A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7741359B2 (en) * | 2005-05-27 | 2010-06-22 | Antibe Therapeutics Inc. | Hydrogen sulfide derivatives of non-steroidal anti-inflammatory drugs |
| DK2057139T3 (da) * | 2006-07-18 | 2013-11-18 | Antibe Holdings Inc | Hydrogensulfidderivater af non-steroide anti-inflammatoriske lægemidler |
| ITMI20080382A1 (it) * | 2008-03-07 | 2009-09-08 | Ctg Pharma S R L | Composizioni farmaceutiche oculari |
| ITMI20081167A1 (it) * | 2008-06-26 | 2009-12-27 | Ctg Pharma S R L | Composizioni farmaceutiche per il trattamento di malattie neurodegenerative |
| US8541396B2 (en) | 2009-04-24 | 2013-09-24 | National University Of Singapore | Morpholin-4-ium 4 methoxyphenyl (morpholino) phosphinodithioate (GYY4137) as a novel vasodilator agent |
| WO2011053597A1 (en) * | 2009-10-26 | 2011-05-05 | The University Of Memphis Research Foundation | Pipemidic acid derivative autotaxin inhibitors |
| US9242009B2 (en) | 2012-07-17 | 2016-01-26 | The General Hospital Corporation | Compositions and methods to treat neurodegenerative diseases |
| AU2017263574B2 (en) | 2016-05-12 | 2022-11-17 | The Regents Of The University Of Michigan | ASH1L inhibitors and methods of treatment therewith |
| WO2019094772A1 (en) | 2017-11-10 | 2019-05-16 | The Regents Of The University Of Michigan | Ash1l degraders and methods of treatment therewith |
| JP2021066660A (ja) * | 2018-02-09 | 2021-04-30 | アピオン・ジャパン有限会社 | Ｔｉｒａｐ阻害剤 |
| WO2022115952A1 (en) * | 2020-12-03 | 2022-06-09 | Antibe Therapeutics Inc. | [1-(4-chloro-benzoyl)-5-methoxy-2-methyl-1h-indol-3-yl]-acetic acid 4-thiocarbamoyl-phenyl ester for the treatment of a viral infection |
| WO2023159296A1 (en) * | 2022-02-28 | 2023-08-31 | Antibe Therapeutics Inc. | 4-thiocarbamoylphenyl 2-(4-oxophenyl)-phenyl propanoate for the treatment of pain associated with urologic chronic pelvic pain syndrome |
| GR1010438B (el) * | 2022-03-21 | 2023-04-06 | UNI-PHARMA ΚΛΕΩΝ ΤΣΕΤΗΣ ΦΑΡΜΑΚΕΥΤΙΚΑ ΕΡΓΑΣΤΗΡΙΑ ΑΒΕΕ με δ.τ. "UNI-PHARMA ABEE", | Φαρμακευτικες ενωσεις που βασιζονται στο συνδυασμο ενος ανταγωνιστη της ισταμινης και ενος δοτη υδροθειου για χρηση στην αντιμετωπιση του κνησμου |
| WO2025076616A1 (en) * | 2023-10-11 | 2025-04-17 | Antibe Therapeutics Inc. | Polymorphic forms of otenaproxesul and compositions and uses thereof |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE612252A (https=) * | 1961-01-05 | |||
| US4170654A (en) * | 1976-02-13 | 1979-10-09 | Merck & Co., Inc. | Antihypertensive compositions containing N-heterocyclicalanines and α- |
| US4112095A (en) * | 1976-10-07 | 1978-09-05 | American Cyanamid Company | 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents |
| US5214191A (en) * | 1990-05-22 | 1993-05-25 | Cortech, Inc. | Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase |
| US5663416A (en) * | 1990-05-22 | 1997-09-02 | Cortech Inc. | Oxidant sensitive and insensitive aromatic esters as inhibitors of human neutrophil elastase |
| EP0937711A1 (de) | 1998-02-18 | 1999-08-25 | Roche Diagnostics GmbH | Neue Thiobenzamide, Verfahren zu ihrer Herstellung sowie diese enthaltende Arzneimittel |
| IT1311924B1 (it) * | 1999-04-13 | 2002-03-20 | Nicox Sa | Composti farmaceutici. |
| IT1314184B1 (it) * | 1999-08-12 | 2002-12-06 | Nicox Sa | Composizioni farmaceutiche per la terapia di condizioni di stressossidativo |
| US6429223B1 (en) * | 2000-06-23 | 2002-08-06 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
| US7638513B2 (en) * | 2004-06-02 | 2009-12-29 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
| EP1630164A1 (en) * | 2004-08-31 | 2006-03-01 | Expotrend Company SA | Pyrazolopyrimidinones as phosphodiesterase inhibitors |
| EP1645288A1 (en) * | 2004-10-07 | 2006-04-12 | CTG Pharma S.r.l. | New nuclear transcription factors regulators |
| CN2757375Y (zh) * | 2004-11-25 | 2006-02-08 | 富士康(昆山)电脑接插件有限公司 | 电子卡连接器 |
| EP1836160A1 (en) * | 2004-12-24 | 2007-09-26 | CTG Pharma S.r.l. | Compounds for treating metabolic syndrome |
| CA2601381A1 (en) | 2005-03-24 | 2006-09-28 | Nycomed Gmbh | 6-thioamide substituted benzimidazoles |
| ITMI20050680A1 (it) * | 2005-04-18 | 2006-10-19 | Ctg Pharma S R L | Nuovi composti anti-infiammatori |
| US7498355B2 (en) | 2005-05-27 | 2009-03-03 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
| WO2006125293A1 (en) * | 2005-05-27 | 2006-11-30 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
| US20060270635A1 (en) | 2005-05-27 | 2006-11-30 | Wallace John L | Derivatives of 4- or 5-aminosalicylic acid |
| DK2057139T3 (da) * | 2006-07-18 | 2013-11-18 | Antibe Holdings Inc | Hydrogensulfidderivater af non-steroide anti-inflammatoriske lægemidler |
-
2007
- 2007-07-18 DK DK07763931.8T patent/DK2057139T3/da active
- 2007-07-18 BR BRPI0714330-3A patent/BRPI0714330A2/pt not_active IP Right Cessation
- 2007-07-18 JP JP2009519765A patent/JP5529534B2/ja not_active Expired - Fee Related
- 2007-07-18 RU RU2009105491/04A patent/RU2468019C2/ru active
- 2007-07-18 BR BRPI0714466A patent/BRPI0714466B8/pt active IP Right Grant
- 2007-07-18 KR KR1020097001029A patent/KR101450653B1/ko active Active
- 2007-07-18 NZ NZ573996A patent/NZ573996A/en not_active IP Right Cessation
- 2007-07-18 ES ES07763931.8T patent/ES2437223T3/es active Active
- 2007-07-18 CA CA002658429A patent/CA2658429A1/en not_active Abandoned
- 2007-07-18 JP JP2009519769A patent/JP5408719B2/ja active Active
- 2007-07-18 WO PCT/CA2007/001273 patent/WO2008009118A1/en not_active Ceased
- 2007-07-18 MX MX2009000749A patent/MX2009000749A/es active IP Right Grant
- 2007-07-18 US US12/374,273 patent/US8314140B2/en not_active Expired - Fee Related
- 2007-07-18 WO PCT/CA2007/001289 patent/WO2008009127A1/en not_active Ceased
- 2007-07-18 PL PL07763931T patent/PL2057139T3/pl unknown
- 2007-07-18 EP EP07763921.9A patent/EP2041108B1/en not_active Not-in-force
- 2007-07-18 AU AU2007276679A patent/AU2007276679B2/en not_active Ceased
- 2007-07-18 AU AU2007276621A patent/AU2007276621B2/en active Active
- 2007-07-18 KR KR1020097001128A patent/KR101495520B1/ko not_active Expired - Fee Related
- 2007-07-18 MX MX2009000750A patent/MX2009000750A/es active IP Right Grant
- 2007-07-18 EP EP07763931.8A patent/EP2057139B1/en active Active
- 2007-07-18 CA CA2658433A patent/CA2658433C/en active Active
- 2007-07-18 RU RU2009105498/04A patent/RU2465271C2/ru not_active IP Right Cessation
- 2007-07-18 PT PT77639318T patent/PT2057139E/pt unknown
-
2008
- 2008-12-28 IL IL196229A patent/IL196229A/en active IP Right Grant
- 2008-12-28 IL IL196228A patent/IL196228A0/en unknown
-
2009
- 2009-02-17 NO NO20090764A patent/NO20090764L/no not_active Application Discontinuation
- 2009-02-17 NO NO20090763A patent/NO342083B1/no unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009543811A5 (https=) | ||
| JP2009543813A5 (https=) | ||
| Bhosle et al. | Mutual Prodrug Concept: F Mutual Prodrug Concept: Fundamentals and undamentals and Applications | |
| JP2008542209A5 (https=) | ||
| JP6566886B2 (ja) | 安定化スルフォラファン | |
| Hasegawa et al. | Design and synthesis of polymeric hydrogen sulfide donors | |
| Bhandari et al. | Design, synthesis and evaluation of antiinflammatory, analgesic and ulcerogenicity studies of novel S-substituted phenacyl-1, 3, 4-oxadiazole-2-thiol and Schiff bases of diclofenac acid as nonulcerogenic derivatives | |
| JP5221341B2 (ja) | ４−または５−アミノサリチル酸誘導体 | |
| JP5408719B2 (ja) | 非ステロイド系抗炎症薬の硫化水素誘導体 | |
| JP2009539777A5 (https=) | ||
| Hegde et al. | Hydrogen sulfide in inflammation: friend or foe? | |
| US20090253799A1 (en) | Divalent hydrazide compound conjugates for inhibiting cystic fibrosis transmembrane conductance regulator | |
| Kadela-Tomanek et al. | Betulin-1, 4-quinone hybrids: Synthesis, anticancer activity and molecular docking study with NQO1 enzyme | |
| CA2414150A1 (en) | Modified forms of nonsteroidal anti-inflammatory drugs and uses thereof | |
| Piplani et al. | Synthesis and characterization of N-Mannich based prodrugs of ciprofloxacin and norfloxacin: In vitro anthelmintic and cytotoxic evaluation | |
| CN107257786A (zh) | 制备噁噻嗪样化合物的方法 | |
| CA3003628A1 (en) | Dendrimer compositions and use in treatment of necrotizing enterocolitis and other gastrointestinal disorders | |
| WO2015118497A1 (fr) | Conjugués et pro-drogues pour le traitement du cancer et de maladies inflammatoires | |
| CA2827887A1 (en) | No- and h2s-releasing compounds | |
| US7666907B2 (en) | Salts of trimebutine and N-desmethyl trimebutine | |
| WO2013168021A1 (en) | Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders | |
| Beattie et al. | The in vivo gastrointestinal activity of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity | |
| US9044491B2 (en) | Method for improving blood flow using stilbenoid derivatives | |
| Mishra et al. | Pectin, beta-cyclodextrin, chitosan and albumin based gastroprotective systems for piroxicam maleate: Synthesis, characterization and biological evaluation | |
| CN100460413C (zh) | 羧酸类非甾体抗炎药与氨基葡萄糖或其盐合成的化合物及其合成方法和应用 |